Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)
Alexander Egeberg, Jacob P. Thyssen
Abstract
Recent observational data have suggested an increased risk of cerebrovascular accidents associated with exposure to risankizumab. This article discusses these findings and highlights why there is a need for future observational studies investigating this potential signal.
Topics & Concepts
Adverse Event Reporting SystemFood and drug administrationObservational studyMedicineAdverse effectDrugIntensive care medicineMedical emergencyInternal medicinePharmacologyPharmacovigilance and Adverse Drug ReactionsDrug-Induced Adverse ReactionsPharmaceutical studies and practices